

Conflict of interest statement:


Glynis P. Ross has received financial support from AMSL, Medtronic, Eli Lilly, NovoNordisk, Sanofi, Novartis, and Merck Sharp & Dohme for the independent development and delivery of lectures.

Signed:  Date: 10-MAY-2016

Henrik Falhammar has received research funding from the Magn. Bergvalls Foundation, Karolinska Institutet, and Stockholm County Council, and financial support from Boehringer Ingelheim, AstraZeneca, Merck Sharp & Dohme, Sanofi, NovoNordisk, and Ipsen for delivery of lectures.

Signed:  Date: 10/5/2016

Roger Chen has received financial support from and/or served on advisory boards for Novo Nordisk, Merck Sharp & Dohme, Novartis, AstraZeneca, and Janssen Cilag, and received an educational grant from Boehringer Ingelheim.

Signed:  Date: 10/5/2016

Helen Barraclough is an employee of Eli Lilly Australia & New Zealand.

Signed: _____ Date: _____

Ole Kleivenes is a former employee of Eli Lilly Australia & New Zealand.

Signed: _____ Date: _____

Ian Gallen has received speaker fees from Eli Lilly and NovoNordisk, and provides educational events for patients and healthcare professionals, funded by Animas Corporation and Eli Lilly, respectively.

Signed: _____ Date: _____

Conflict of interest statement:

Glynis P. Ross has received financial support from AMSL, Medtronic, Eli Lilly, NovoNordisk, Sanofi, Novartis, and Merck Sharp & Dohme for the independent development and delivery of lectures.

Signed: _____ Date: _____

Henrik Falhammar has received research funding from the Magn. Bergvalls Foundation, Karolinska Institutet, and Stockholm County Council, and financial support from Boehringer Ingelheim, AstraZeneca, Merck Sharp & Dohme, Sanofi, NovoNordisk, and Ipsen for delivery of lectures.

Signed: _____ Date: _____

Roger Chen has received financial support from and/or served on advisory boards for Novo Nordisk, Merck Sharp & Dohme, Novartis, AstraZeneca, and Janssen Cilag, and received an educational grant from Boehringer Ingelheim.

Signed: _____ Date: _____

Helen Barraclough is an employee of Eli Lilly Australia & New Zealand.

Signed:  _____ Date: 10/5/2016

Ole Kleivenes is a former employee of Eli Lilly Australia & New Zealand.

Signed: _____ Date: _____

Ian Gallen has received speaker fees from Eli Lilly and NovoNordisk, and provides educational events for patients and healthcare professionals, funded by Animas Corporation and Eli Lilly, respectively.

Signed: _____ Date: _____

Conflict of interest statement:

Glynis P. Ross has received financial support from AMSL, Medtronic, Eli Lilly, NovoNordisk, Sanofi, Novartis, and Merck Sharp & Dohme for the independent development and delivery of lectures.

Signed: _____ Date: _____

Henrik Falhammar has received research funding from the Magn. Bergvalls Foundation, Karolinska Institutet, and Stockholm County Council, and financial support from Boehringer Ingelheim, AstraZeneca, Merck Sharp & Dohme, Sanofi, NovoNordisk, and Ipsen for delivery of lectures.

Signed: _____ Date: _____


Roger Chen has received financial support from and/or served on advisory boards for Novo Nordisk, Merck Sharp & Dohme, Novartis, AstraZeneca, and Janssen Cilag, and received an educational grant from Boehringer Ingelheim.

Signed: _____ Date: _____

Helen Barraclough is an employee of Eli Lilly Australia & New Zealand.

Signed: _____ Date: _____

Ole Kleivenes is a former employee of Eli Lilly Australia & New Zealand.

Signed:  _____ Date: 11.05.16

Ian Gallen has received speaker fees from Eli Lilly and NovoNordisk, and provides educational events for patients and healthcare professionals, funded by Animas Corporation and Eli Lilly, respectively.

Signed: _____ Date: _____

